Prosecution Insights
Last updated: July 17, 2026
Application No. 18/713,901

COMPOSITIONS AND METHODS FOR INDUCING ESR1, PI3K, HER2, AND HER3 IMMUNE RESPONSES

Non-Final OA §101§DP
Filed
May 28, 2024
Priority
Nov 29, 2021 — CIP of 11/510,975 +2 more
Examiner
CHESTNUT, BARRY A
Art Unit
Tech Center
Assignee
Replicate Bioscience Inc.
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
7m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
545 granted / 742 resolved
+13.5% vs TC avg
Moderate +6% lift
Without
With
+6.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
25 currently pending
Career history
755
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
65.2%
+25.2% vs TC avg
§102
11.8%
-28.2% vs TC avg
§112
8.0%
-32.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 742 resolved cases

Office Action

§101 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Priority This application is a 371 of PCT/US22/80522 filed 11/28/2022, which claims the benefit of priority to U.S. Patent Application Serial No. 17/537,199, filed on November 29, 2021 that is hereby acknowledged by the Examiner. Status of the Claims The amendment dated 11/08/2015 is acknowledged. Claims 1-17,19, 21 and 26 are pending and under examination. Information Disclosure Statement The information disclosure statement (IDS) submitted on 08/09/2024, 12/27/2024, 01/08/2025 and 06/26/2025 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement(s) is/are being considered by the Examiner. Drawings The drawing filed on 05/28/2024 are acknowledged and accepted by the Examiner. Specification The disclosure is objected to because of the following informalities: The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code (see paragraph [0110]). Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01. Appropriate correction is required. Double Patenting Claims 1-17, 19, 21 and 26 of this application are patentably indistinct from claims 1-17, 19, 21 and 26 of US Patent No. 11510975. Pursuant to 37 CFR 1.78(f), when two or more applications filed by the same applicant or assignee contain patentably indistinct claims, elimination of such claims from all but one application may be required in the absence of good and sufficient reason for their retention during pendency in more than one application. Applicant is required to either cancel the patentably indistinct claims from all but one application or maintain a clear line of demarcation between the applications. See MPEP § 822. Claims 1-17, 19, 21 and 26 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-17, 19, 21 and 26 of prior U.S. Patent No. 11510975. This is a statutory double patenting rejection. A rejection based on double patenting of the “same invention” type finds its support in the language of 35 U.S.C. 101 which states that “whoever invents or discovers any new and useful process... may obtain a patent therefor...” (Emphasis added). Thus, the term “same invention,” in this context, means an invention drawn to identical subject matter. See Miller v. Eagle Mfg. Co., 151 U.S. 186 (1894); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Ockert, 245 F.2d 467, 114 USPQ 330 (CCPA 1957). A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Barry Chestnut whose telephone number is (571)270-3546. The examiner can normally be reached on M-Th 8:00 to 4:00. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas Visone can be reached on 571-270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BARRY A CHESTNUT/Primary Examiner, Art Unit 1672
Read full office action

Prosecution Timeline

May 28, 2024
Application Filed
Jun 12, 2026
Non-Final Rejection mailed — §101, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679869
RECOMBINANT HIV ENV POLYPEPTIDES AND THEIR USES
5y 1m to grant Granted Jul 14, 2026
Patent 12678468
Method for Reducing the Population of at Least One Intestinal and/or Gastrointestinal Bacteria Species Comprising Bacteriophages, and Bacteriophages and the Use Thereof
3y 2m to grant Granted Jul 14, 2026
Patent 12673102
METHOD FOR IMPROVING IMMUNOGENICITY OF PROTEIN/PEPTIDE ANTIGEN
3y 8m to grant Granted Jul 07, 2026
Patent 12673097
IMPROVED DNA VACCINE FOR SARS-COV-2
3y 3m to grant Granted Jul 07, 2026
Patent 12661394
CORONAVIRUS VACCINE
3y 9m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
80%
With Interview (+6.1%)
2y 8m (~7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 742 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month